ONC — Oncolytics Biotech Balance Sheet
0.000.00%
- CA$61.62m
- CA$45.76m
Annual balance sheet for Oncolytics Biotech, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 31.2 | 41.3 | 32.1 | 34.9 | 16.9 |
Net Total Receivables | 0.09 | 0.866 | 0.521 | 0.015 | 0.068 |
Prepaid Expenses | |||||
Total Current Assets | 33.7 | 44.9 | 35.7 | 38.2 | 18.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.609 | 0.976 | 0.652 | 0.647 | 1.31 |
Other Long Term Assets | |||||
Total Assets | 34.3 | 45.9 | 37.3 | 38.8 | 20.2 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.71 | 2.69 | 3.94 | 4.24 | 6.69 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.59 | 9.78 | 10.8 | 11.3 | 14.2 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 24.8 | 36.1 | 26.5 | 27.6 | 5.98 |
Total Liabilities & Shareholders' Equity | 34.3 | 45.9 | 37.3 | 38.8 | 20.2 |
Total Common Shares Outstanding |